BTK and B-cell chronic lymphocytic leukemia: Given the significant success of Btk inhibition in CLL and MCL, the efficacy of Btk inhibition in rel/ref FL was explored in a phase 2 trial of ibrutinib monotherapy (DAWN trial) [78].